GeneCentric Therapeutics will present the first data on novel response signatures for metastatic, muscle invasive bladder cancer (MIBC) treatments by applying its proprietary, RNA-sequencing based predictive response signature and Cancer Subtyping Platform (CSP®).  The initial response signature and MIBC cohort data are being presented at a poster session at the annual meeting of the American […]

GeneCentric Therapeutics, Inc. collaborator Dr. Tracy Rose from the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC presented at the Genitourinary Cancers Symposium today on: “Fibroblast growth factor receptor status and response to immune checkpoint inhibition in metastatic urothelial cancer.” Through a collaboration announced in December 2018 with UNC Lineberger Comprehensive Cancer Center (UNC-LCCC) and […]

CEO Dr. Myla Lai-Goldman named Executive Chairperson Durham, NC, January 3, 2019 -GeneCentric Therapeutics, Inc. today announced the appointment of Michael V. Milburn, PhD, as Chief Executive Officer and President and will join GeneCentric’s Board of Directors. Dr. Myla Lai-Goldman, founder, current CEO and President, will assume the newly-created role of Executive Chairperson of the […]

Dr. Myla Lai-Goldman discusses GeneCentric’s Cancer Subtyping Platform (CSP™) with Healtheo360’s David Duplay and Courtland Long

On January 26, 2016 at 2:00 pm, GeneCentric’s Hawazin Faruki will speak at the Personalized Medicine World Conference (PMWC) 2016 Silicon Valley on “Genomic Tumor Profiling – Advancing Beyond Gene Mutations.” PMWC 2016 SV, co-hosted with Stanford Health Care and UCSF on January 24-27, will gather 1200 multidisciplinary attendees and key stakeholders from the business, […]

On May 5, 2015, GeneCentric will present at the Southeast Investor & Venture Philanthropy Oncology Summit 2015. The Summit features more than 30 of the Southeast’s top private oncology companies. Attendees come from small and large oncology-focused companies, venture philanthropies and investment groups.

Title: “Fibroblast growth factor receptor status and response to immune checkpoint inhibition in metastatic urothelial cancer.” Abstract Number: 458 Date:  February 15, 2019 Presenter: Tracy L. Rose, MD, MPH, Assistant Professor, Division of Hematology/Oncology, UNC Department of Medicine, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC To read the abstract, please visit: https://meetinglibrary.asco.org/record/169672/abstract View the poster here  

Mayhew G, Perou C, Hayes N, Lai-Goldman M, and Faruki H.

Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M.